Foluso Fakorede, MD, an interventional cardiologist with Cardiovascular Solutions of Central Mississippi, says these issues are typically overlooked in today's healthcare environment. 

U.S. physicians often receive payments from medical device manufacturers and pharmaceutical companies. New research in JAMA found a connection between receiving such payments and using specific devices—should the industry be concerned? 

The bioresorbable stent, examined at length for the LIFE-BTK clinical trial, stays in place for up to three years before completely dissolving. 

Five of the largest U.S. medical societies focused on cardiovascular health are one step closer to seeing their paradigm-shifting proposal become a reality.

The new-look catheter came out of a medical device incubator started by entrepreneur Eitan Konstantino, PhD, who has years of experience in the vascular space. 

The Society for Cardiovascular Angiography & Interventions and Society of Thoracic Surgeons have both shared statements in support of the ban, which is already being challenged in court. The American Hospital Association, meanwhile, opposes the policy shift, saying it “errs by seeking to create a one-size-fits-all rule”

Alison Bailey, MD, co-chair of the business of cardiology sessions at ACC.24, emphasized that reimbursement cuts can have a long-term negative impact on patient. 

How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview.